» Articles » PMID: 22829805

Circulating Levels of MicroRNA from Children with Newly Diagnosed Type 1 Diabetes and Healthy Controls: Evidence That MiR-25 Associates to Residual Beta-cell Function and Glycaemic Control During Disease Progression

Overview
Specialty Endocrinology
Date 2012 Jul 26
PMID 22829805
Citations 153
Authors
Affiliations
Soon will be listed here.
Abstract

This study aims to identify key miRNAs in circulation, which predict ongoing beta-cell destruction and regeneration in children with newly diagnosed Type 1 Diabetes (T1D). We compared expression level of sera miRNAs from new onset T1D children and age-matched healthy controls and related the miRNAs expression levels to beta-cell function and glycaemic control. Global miRNA sequencing analyses were performed on sera pools from two T1D cohorts (n = 275 and 129, resp.) and one control group (n = 151). We identified twelve upregulated human miRNAs in T1D patients (miR-152, miR-30a-5p, miR-181a, miR-24, miR-148a, miR-210, miR-27a, miR-29a, miR-26a, miR-27b, miR-25, miR-200a); several of these miRNAs were linked to apoptosis and beta-cell networks. Furthermore, we identified miR-25 as negatively associated with residual beta-cell function (est.: -0.12, P = 0.0037), and positively associated with glycaemic control (HbA1c) (est.: 0.11, P = 0.0035) 3 months after onset [corrected]. In conclusion this study demonstrates that miR-25 might be a "tissue-specific" miRNA for glycaemic control 3 months after diagnosis in new onset T1D children and therefore supports the role of circulating miRNAs as predictive biomarkers for tissue physiopathology and potential intervention targets.

Citing Articles

Downregulation of and Its Impact on and Expression in Type 2 Diabetes Mellitus: Implications for Biomarker Discovery and Disease Pathogenesis.

Rattanapan Y, Nongwa K, Supanpong C, Satsadeedat C, Sai-Ong T, Kooltheat N J Clin Med Res. 2024; 16(11):536-546.

PMID: 39635336 PMC: 11614410. DOI: 10.14740/jocmr6099.


The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets.

Li X, Qian B, Chen X, Shen M, Zhao S, Zhang X Front Immunol. 2024; 15:1464327.

PMID: 39606232 PMC: 11599204. DOI: 10.3389/fimmu.2024.1464327.


Circulating hsa-miR-320a and its regulatory network in type 1 diabetes mellitus.

Nizam R, Malik M, Jacob S, Alsmadi O, Koistinen H, Tuomilehto J Front Immunol. 2024; 15:1376416.

PMID: 39464889 PMC: 11502356. DOI: 10.3389/fimmu.2024.1376416.


Suitability evaluation of toehold switch and EXPAR for cell-free MicroRNA biosensor development.

Copeland C, Kwon Y Biotechnol Notes. 2024; 4:83-89.

PMID: 39416922 PMC: 11446392. DOI: 10.1016/j.biotno.2023.11.003.


Importance of Studying Non-Coding RNA in Children and Adolescents with Type 1 Diabetes.

Cabiati M, Federico G, Del Ry S Biomedicines. 2024; 12(9).

PMID: 39335501 PMC: 11429055. DOI: 10.3390/biomedicines12091988.


References
1.
Rayner K, Esau C, Hussain F, McDaniel A, Marshall S, van Gils J . Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011; 478(7369):404-7. PMC: 3235584. DOI: 10.1038/nature10486. View

2.
Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M . MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011; 474(7353):649-53. DOI: 10.1038/nature10112. View

3.
Fei J, Li Y, Zhu X, Luo X . miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML). PLoS One. 2012; 7(3):e32834. PMC: 3307705. DOI: 10.1371/journal.pone.0032834. View

4.
Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z . MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep. 2011; 27(2):594-8. DOI: 10.3892/or.2011.1530. View

5.
Aly H, Gottlieb P . The honeymoon phase: intersection of metabolism and immunology. Curr Opin Endocrinol Diabetes Obes. 2009; 16(4):286-92. DOI: 10.1097/MED.0b013e32832e0693. View